XLRN — Acceleron Pharma Share Price
Last Trade - 00:00- $7.60bn
- $6.98bn
- $101.13m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 27.77 | 13.48 | 13.99 | 73.99 | 92.52 | 134.56 | 211.45 | 38.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
Directors
- Francois Nader NEC (64)
- Habib Dable (51)
- Kevin Mclaughlin (64)
- Jay Backstrom (66)
- Sujay Kango (57)
- Adam Veness (35)
- Laura Hamill (56)
- Christopher Hite (54)
- Terrence Kearney (66)
- Kemal Malik (58)
- Thomas McCourt (64)
- Karen Smith IND (53)
- Joseph Zakrzewski (58)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- June 13th, 2003
- Public Since
- September 18th, 2013
- No. of Shareholders
- 48
- No. of Employees
- 312
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 60,900,521
- Address
- 128 Sidney St, CAMBRIDGE, 02139-4239
- Web
- http://www.acceleronpharma.com/
- Phone
- +1 6176499200
- Contact
- Jamie Bernard
- Auditors
- Ernst & Young LLP
Latest News for XLRN
Upcoming events for XLRN
Q3 2021 Acceleron Pharma Inc Earnings Release
Similar to XLRN
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
89BIO ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
ADAGIO THERAPEUTICS ORD
NASDAQ Global Market
FAQ
As of Today at 19:54 UTC, shares in Acceleron Pharma are trading at $124.81. This share price information is delayed by 15 minutes.
Shares in Acceleron Pharma last closed at $124.81 and the price had moved by +32.59% over the past 365 days. In terms of relative price strength the Acceleron Pharma share price has outperformed the S&P500 Index by +0.6% over the past year.
The overall consensus recommendation for Acceleron Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Acceleron Pharma does not currently pay a dividend.
Acceleron Pharma does not currently pay a dividend.
Acceleron Pharma does not currently pay a dividend.
To buy shares in Acceleron Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $124.81, shares in Acceleron Pharma had a market capitalisation of $7.60bn.
Here are the trading details for Acceleron Pharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: XLRN
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Acceleron Pharma does not currently have a style classification.
The analyst consensus target price for shares in Acceleron Pharma is $154.50. That is 23.79% above the last closing price of $124.81.
Analysts covering Acceleron Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$3.92 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acceleron Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -15.52%.
As of the last closing price of $124.81, shares in Acceleron Pharma were trading -0.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acceleron Pharma.
Acceleron Pharma's management team is headed by:
- Francois Nader - NEC
- Habib Dable -
- Kevin Mclaughlin -
- Jay Backstrom -
- Sujay Kango -
- Adam Veness -
- Laura Hamill -
- Christopher Hite -
- Terrence Kearney -
- Kemal Malik -
- Thomas McCourt -
- Karen Smith - IND
- Joseph Zakrzewski -
We do not have data on Acceleron Pharma's shareholders